tradingkey.logo

Evolus Inc

EOLS
6.900USD
+0.050+0.73%
收盤 12/26, 16:00美東報價延遲15分鐘
446.89M總市值
虧損本益比TTM

Evolus Inc

6.900
+0.050+0.73%

關於 Evolus Inc 公司

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.

Evolus Inc簡介

公司代碼EOLS
公司名稱Evolus Inc
上市日期Feb 08, 2018
CEOMoatazedi (David)
員工數量332
證券類型Ordinary Share
年結日Feb 08
公司地址520 Newport Center Dr Ste 1200
城市NEWPORT BEACH
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編92660-7022
電話19492844555
網址https://www.evolus.com/
公司代碼EOLS
上市日期Feb 08, 2018
CEOMoatazedi (David)

Evolus Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
--
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
名稱
名稱/職務
職務
持股
持股變動
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
--
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Nantahala Capital Management, LLC
8.84%
Tang Capital Management, LLC
8.47%
Lynch (Timothy Patrick)
7.92%
Caligan Partners, LP
6.39%
BlackRock Institutional Trust Company, N.A.
6.15%
其他
62.24%
持股股東
持股股東
佔比
Nantahala Capital Management, LLC
8.84%
Tang Capital Management, LLC
8.47%
Lynch (Timothy Patrick)
7.92%
Caligan Partners, LP
6.39%
BlackRock Institutional Trust Company, N.A.
6.15%
其他
62.24%
股東類型
持股股東
佔比
Hedge Fund
38.96%
Investment Advisor
22.15%
Investment Advisor/Hedge Fund
15.60%
Individual Investor
10.06%
Private Equity
4.06%
Corporation
3.30%
Research Firm
2.38%
Pension Fund
0.47%
Bank and Trust
0.30%
其他
2.73%

機構持股

更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
356
58.38M
89.22%
--
2025Q3
366
58.59M
90.20%
-409.50K
2025Q2
368
58.97M
91.09%
+3.93M
2025Q1
354
55.05M
88.70%
-1.35M
2024Q4
343
52.59M
87.55%
+1.63M
2024Q3
334
50.95M
89.20%
-1.08M
2024Q2
328
52.17M
86.99%
+2.08M
2024Q1
314
50.10M
82.52%
-553.42K
2023Q4
296
45.99M
83.45%
+2.48M
2023Q3
294
41.91M
82.26%
+3.40M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Nantahala Capital Management, LLC
4.20M
6.49%
+546.58K
+14.97%
Jun 30, 2025
Tang Capital Management, LLC
5.00M
7.73%
--
--
Jun 30, 2025
Lynch (Timothy Patrick)
4.09M
6.33%
+4.09M
--
Aug 11, 2025
Caligan Partners, LP
3.34M
5.17%
+610.82K
+22.36%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.65M
5.64%
-175.30K
-4.58%
Jun 30, 2025
The Vanguard Group, Inc.
3.31M
5.11%
+84.18K
+2.61%
Jun 30, 2025
Frazier Life Sciences Management, L.P.
2.44M
3.77%
+2.44M
--
Jun 30, 2025
Medy Tox Inc
2.14M
3.3%
-1.24M
-36.82%
Dec 31, 2024
Millennium Management LLC
1.48M
2.29%
+91.40K
+6.57%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
State Street SPDR S&P Pharmaceuticals ETF
0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.93%
iShares U.S. Pharmaceuticals ETF
0.15%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
查看更多
State Street SPDR S&P Pharmaceuticals ETF
佔比0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比0.93%
iShares U.S. Pharmaceuticals ETF
佔比0.15%
iShares Micro-Cap ETF
佔比0.07%
ProShares Ultra Nasdaq Biotechnology
佔比0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.06%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
ProShares Hedge Replication ETF
佔比0.02%
iShares Russell 2000 Growth ETF
佔比0.02%
Schwab U.S. Small-Cap ETF
佔比0.01%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Evolus Inc的前五大股東是誰?

Evolus Inc的前五大股東如下:
Nantahala Capital Management, LLC
持有股份:4.20M
佔總股份比例:6.49%。
Tang Capital Management, LLC
持有股份:5.00M
佔總股份比例:7.73%。
Lynch (Timothy Patrick)
持有股份:4.09M
佔總股份比例:6.33%。
Caligan Partners, LP
持有股份:3.34M
佔總股份比例:5.17%。
BlackRock Institutional Trust Company, N.A.
持有股份:3.65M
佔總股份比例:5.64%。

Evolus Inc的前三大股東類型是什麼?

Evolus Inc 的前三大股東類型分別是:
Nantahala Capital Management, LLC
Tang Capital Management, LLC
Lynch (Timothy Patrick)

有多少機構持有Evolus Inc(EOLS)的股份?

截至2025Q4,共有356家機構持有Evolus Inc的股份,合計持有的股份價值約為58.38M,占公司總股份的89.22% 。與2025Q3相比,機構持股有所增加,增幅為-0.98%。

哪個業務部門對Evolus Inc的收入貢獻最大?

在--,--業務部門對Evolus Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI